Enterome - Model EO2463 -B-Cell Malignancies Drug

With EO2463, Enterome aims to induce a highly specific cytotoxic immune reaction against B lymphocytes, and to target the malignant B cells which are enriched in patients with B-cell Non-Hodgkin lymphomas and leukemias.

EO2463 is being prepared as a clinical candidate for trials to start in 2021.